Author Archives: Alberto Molano, PhD

Australian researcher David Geoffrey Chapman has been awarded $100,000 by the American Thoracic Society (ATS) Foundation and ResMed to investigate how non-invasive ventilation can help improve sleep patterns in patients with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) overlap syndrome. Dr. Chapman, BSc, PhD,…

Piedmont Atlanta announced that it is the first hospital in the state of Georgia to offer treatment for emphysema with the Zephyr Valve System, a minimally invasive therapy for better lung function and exercise tolerance without the need for surgery. Patients with emphysema, a severe form of chronic…

Azithromycin treatment initiated during hospitalization for an acute exacerbation of chronic obstructive pulmonary disease (COPD), followed by three months of a low-maintenance dose, seems to reduce treatment failure. The results were reported in “Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicentre, Randomized, Double-blind, Placebo-controlled Trial,” published in…

Canadian wellness app Carrot Rewards has announced a new campaign in collaboration with The Lung Association — Ontario and Boehringer Ingelheim (Canada) to reach chronic obstructive pulmonary disease (COPD) patients and educate users about the disease. Carrot Rewards is an artificial intelligence-driven wellness app and brand engagement…

Circassia announced that the U.S. Food and Drug Administration (FDA) approved its medication Duaklir for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company plans to launch the therapy in the United States in the second half of 2019. Duaklir is a combination of two…

A relatively new non-invasive imaging technique, called parametric response mapping (PRM), can identify damage in the smallest airways, opening the possibility of detecting specific lung changes earlier (when it is most treatable) in patients with chronic obstructive pulmonary disease (COPD), and allowing doctors to more accurately measure the response…

Nuvaira, a medical device company, announced it has secured $79 million to support the AIRFLOW-3 clinical trial to assess the company’s new targeted lung denervation (TLD) system, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). COPD includes a group of diseases characterized by chronic airway obstruction…

The U.S. Food and Drug Administration has approved Olympus‘ Spiration Valve System (SVS) as a minimally invasive treatment for severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). The approval is based on positive results from the EMPROVE clinical trial (NCT01812447), which showed meaningful improvements in…

Chronic obstructive pulmonary disease (COPD) is much more common in obese individuals ages 50 and older who have never smoked, according to a study that also shows that the odds of having COPD increases with the level of obesity. Led by researchers at the University of Toronto in Canada, the…